Novel heterocyclic compounds as gata modulators

A composition comprising one or more compounds selected from:

• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopropane carboxylic acid,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,
• 1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,
• 1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,
• 1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,
• 1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(2-Hydroxy-1-phenyl-ethyl amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,
• Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylate,
• {1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid ethylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid tert-butylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,
• 1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,
• N4-tert-Butyl-N2-[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,
• (1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,
• N4-tert-Butyl-N2-[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• N4-tert-Butyl-N2-[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• [4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,
• 1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl)-cyclobutane carboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-}4-[2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.

A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of a compound comprising:

• stereoisomers thereof and/or pharmaceutically acceptable salts of compounds of formula (I) and/or pharmaceutically acceptable salts of the stereoisomers of compounds of formula (I);
• wherein,
• X, Y and Z are each independently selected from N or CRb, wherein Rb is selected from hydrogen, halogen or alkyl;
• with a proviso that when X and Y are each independently N, Z is —CRb and when Y and Z are each independently N, X is —CRb;
• A is a 3 to 7 membered cycloalkyl ring;
• B is an optionally substituted group selected from alkyl, alkoxy, cycloalkyl, aryl, heteroaryl or —NR2R3, wherein one or more optional substituents on B are selected from halogen, hydroxy, cyano, alkyl, haloalkyl, alkoxy, cycloalkyl, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl;
• R1 is selected from hydrogen or alkyl;
• R2 and R3 are each independently selected from hydrogen, —(CH2)n-hydroxy, —(CH2)n-halogen, and an optionally substituted group selected from alkyl, —(CH2)n-cycloalkyl, —(CH2)n-heterocyclyl, —(CH2)n-aryl or —(CH2)n-heteroaryl, wherein one or more optional substituents on R2 and R3 are each independently selected from halogen, cyano, hydroxy, alkyl, cycloalkyl, alkoxy, —CO-alkyl, —COORc, —CONRdRe, —(CH2)nSO2Rf, —(CH2)nSO2NRcRd, aryl, heteroaryl or heterocyclyl;
• or
• R2 and R3 optionally combine with the nitrogen atom, to which they are attached, to form an optionally substituted 5- to 6-membered heterocyclic ring optionally having 1 to 3 additional hetero atoms or groups selected from nitrogen, oxygen, sulfur, SO2 or CO, wherein one or more optional substituents on the heterocyclic ring are selected from halogen, hydroxy, alkoxy, alkyl, cycloalkyl, or —CO-alkyl;
• R4 is hydrogen or an optionally substituted group selected from amino, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl, wherein one or more optional substituents on R4 are selected from halogen, hydroxy, cyano, alkyl, —(CH2)n—OH, cycloalkyl, alkoxy or —CO-alkyl;
• Ra is selected from cyano, —(CH2)n—OH, —(CH2)n-alkoxy, alkyl, aryl, —NH-aryl, heteroaryl, —(CH2)nCO-alkyl, —(CH2)nCOORc, —(CH2)nCONRdRe, —(CH2)nSO2Rf, or —(CH2)nSO2NRcRd;
• Rc is selected from hydrogen, alkyl, cycloalkyl, aryl, heterocyclyl or heteroaryl;
• Rd and Re are each independently selected from hydrogen or an optionally substituted group selected from alkyl, cycloalkyl, alkoxy, aryl, heteroaryl or heterocyclyl, wherein one or more optional substituents on Rd and Re are each independently selected from halogen, hydroxy or alkyl;
• Rf is selected from alkyl, cycloalkyl, heterocyclyl, aryl or heteroaryl;
• and
• n is an integer from 0 to 2.

A method for the treatment of atherosclerosis and/or diabetes in a subject, which comprises administering to the subject a therapeutically effective amount of at least one compound selected from one or more of:

• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclopropane carboxylic acid,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclopentane carboxylic acid,
• 1-[4-(4-tert-Butyl-6-tert-butylamino-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
• 1-(4-{4-[(1-Ethyl-pyrrolidin-2-ylmethyl)-amino]-6-phenyl-pyrimidin-2-ylamino}-phenyl)-cyclobutanecarboxylic acid methyl ester,
• 1-[4-(4-tert-Butylamino-5-fluoro-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-{4-[4-(Bis-cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid methyl ester,
• 1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclopentanecarboxylic acid,
• 1-{4-[4-(Cyclopropylmethyl-amino)-6-(4-fluoro-phenyl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Methylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
• 1-{4-[4-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(Bicyclo[2.2.1]hept-2-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenyl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenyl)-6-(4-hydroxy-piperidin-1-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclobutylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
• 1-{4-[4-(1,1-Dimethyl-propylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Fluoro-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Methanesulfonyl-phenylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-8 4-Phenyl-6-(1-phenyl-ethylamino)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(2-Hydroxy-1-phenyl-ethylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Amino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-{4-[4-(5-Methyl-isoxazol-3-ylamino)-6-phenyl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclopentyl-6-cyclopentylamino-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarboxylic acid,
• 1-[4-(4-tert-Butylamino-6-cyclopentyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(1-Methyl-1H-pyrazol-4-yl)-6-pyrrolidin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Hydroxy-piperidin-1-yl)-6-(1-methyl-1H-pyrazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{3-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-5-methyl-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-piperazin-1-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4-Acetyl-piperazin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(6-Methoxy-pyridin-3-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-(4,4-Difluoro-piperidin-1-yl)-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-tert-Butylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[4-Cyclopentylamino-6-(3,5-dimethyl-isoxazol-4-yl)-pyrimidin-2-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(4-Cyclopentylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutanecarbonitrile,
• Sodium 1-[4-(4-tert-butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylate,
• {1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutyl}-methanol,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid ethylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid dimethylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid tert-butylamide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid amide,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid methoxy-methyl-amide,
• 1-{1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutyl}-ethanone,
• N4-tert-Butyl-N2-[4-(1-oxazol-2-yl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• 1-[4-(4-tert-Butylamino-6-phenyl-pyrimidin-2-ylamino)-phenyl]-cyclobutane carboxylic acid (4-fluoro-phenyl)-amide,
• (1-{4-[4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-ylamino]-phenyl}-cyclobutyl)-methanol,
• N4-tert-Butyl-N2-[4-(1-methoxymethyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• N4-tert-Butyl-N2-[4-(1-methyl-cyclobutyl)-phenyl]-6-phenyl-pyrimidine-2,4-diamine,
• [4-(3,5-Dimethyl-isoxazol-4-yl)-6-morpholin-4-yl-pyrimidin-2-yl]-[4-(1-methanesulfonylmethyl-cyclobutyl)-phenyl]-amine,
• 1-[4-(2-tert-Butylamino-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-{4-[2-(tert-Butyl-methyl-amino)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(6-tert-Butylamino-2-phenyl-pyrimidin-4-ylamino)-phenyl}-cyclobutane carboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-methyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(4-Fluoro-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-]2-(4-Acetyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-(4-fluoro-phenyl)-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(6-Methoxy-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(4-Methanesulfonyl-phenyl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(6-Methyl-pyridin-3-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[2-(1,1-Dioxo-1λ6-thiomorpholin-4-yl)-6-phenyl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-{4-[6-(3,5-Dimethyl-isoxazol-4-yl)-2-morpholin-4-yl-pyrimidin-4-ylamino]-phenyl}-cyclobutanecarboxylic acid,
• 1-[4-(2-Morpholin-4-yl-6-phenyl-pyrimidin-4-ylamino)-phenyl]-cyclobutane carboxylic acid,
• 1-[4-(4-Isopropoxy-6-phenyl-pyrimidin-2-ylamino)-phenyl}-cyclobutane carboxylic acid,
• stereoisomers thereof and/or pharmaceutically acceptable salts of the compounds and/or pharmaceutically acceptable salts of the stereoisomers of the compounds.